Bovie Medical Announces Sales Channel Partnership Agreement with Hologic for J-Plasma®

CLEARWATER, Fla.--()--Bovie Medical (NYSE MKT:BVX), announced a sales channel partnership agreement with Hologic, effective immediately.

“We are proud to partner with a Company of Hologic’s caliber. This agreement is an important milestone in our strategy to scale J-Plasma® through select sales channel partnerships across multiple specialties that represent large addressable market opportunities.”

Hologic will add Bovie’s J-Plasma® product line to its world class portfolio of healthcare solutions in gynecological and gynecological/oncological surgery in three U.S. regions.

The initial six-month agreement provides certain members of Hologic’s direct GYN Surgical sales force with access to J-Plasma® and includes the option to extend the agreement into a worldwide distribution pact that would involve Hologic’s entire surgical sales force.

Bovie Medical’s CEO, Robert L. Gershon noted, “We are proud to partner with a Company of Hologic’s caliber. This agreement is an important milestone in our strategy to scale J-Plasma® through select sales channel partnerships across multiple specialties that represent large addressable market opportunities.”

Commenting on the agreement, Thomas P. O'Neill, Hologic Division President, GYN Surgical Solutions said, “J-Plasma®’s reputation for unparalleled precision and safety makes it an ideal product for surgical procedures involving delicate surrounding tissue and structures. This agreement aligns with our strategy of providing our customers with cutting-edge technology that makes a real difference in patients’ lives.”

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s www.boviemed.com.

Contacts

Investor Relations:
MBS Value Partners
Hugh Collins, 212-223-4632
investor.relations@boviemed.com